Serial assessment of inflammatory biomarkers as a prognostic factor for first-line treatment outcomes in patients with metastatic colorectal cancer: single-center retrospective study
Key Points
Poor survival outcomes can be predicted using inflammatory biomarkers, such as NLR and SII.
Inflammatory biomarkers were assessed over time to evaluate their effectiveness for predicting outcomes.
Assessment method involved the serial evaluation of biomarkers in patients with metastatic colorectal cancer.
These findings highlight the potential of inflammatory biomarkers as a tool for improving treatment strategies.
Abstract
Serial evaluation of NLR and SII could identify patients who are at increased risk of poor survival outcomes.